The landscape of the methodology in drug repurposing using human genomic data: a systematic review
- PMID: 38279645
- PMCID: PMC10818097
- DOI: 10.1093/bib/bbad527
The landscape of the methodology in drug repurposing using human genomic data: a systematic review
Abstract
The process of drug development is expensive and time-consuming. In contrast, drug repurposing can be introduced to clinical practice more quickly and at a reduced cost. Over the last decade, there has been a significant expansion of large biobanks that link genomic data to electronic health record data, public availability of various databases containing biological and clinical information and rapid development of novel methodologies and algorithms in integrating different sources of data. This review aims to provide a thorough summary of different strategies that utilize genomic data to seek drug-repositioning opportunities. We searched MEDLINE and EMBASE databases to identify eligible studies up until 1 May 2023, with a total of 102 studies finally included after two-step parallel screening. We summarized commonly used strategies for drug repurposing, including Mendelian randomization, multi-omic-based and network-based studies and illustrated each strategy with examples, as well as the data sources implemented. By leveraging existing knowledge and infrastructure to expedite the drug discovery process and reduce costs, drug repurposing potentially identifies new therapeutic uses for approved drugs in a more efficient and targeted manner. However, technical challenges when integrating different types of data and biased or incomplete understanding of drug interactions are important hindrances that cannot be disregarded in the pursuit of identifying novel therapeutic applications. This review offers an overview of drug repurposing methodologies, providing valuable insights and guiding future directions for advancing drug repurposing studies.
Keywords: drug repurposing; genetic variants; methodology; systematic review.
Published by Oxford University Press 2024.
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Drug repurposing: Iron in the fire for older drugs.Biomed Pharmacother. 2021 Sep;141:111638. doi: 10.1016/j.biopha.2021.111638. Epub 2021 Jun 18. Biomed Pharmacother. 2021. PMID: 34153846 Review.
-
Drug repurposing: a promising tool to accelerate the drug discovery process.Drug Discov Today. 2019 Oct;24(10):2076-2085. doi: 10.1016/j.drudis.2019.06.014. Epub 2019 Jun 22. Drug Discov Today. 2019. PMID: 31238113 Review.
-
Repurposing Drugs: An Empowering Approach to Drug Discovery and Development.Drug Res (Stuttg). 2023 Nov;73(9):481-490. doi: 10.1055/a-2095-0826. Epub 2023 Jul 21. Drug Res (Stuttg). 2023. PMID: 37478892 Review.
-
System biology approaches for drug repurposing.Prog Mol Biol Transl Sci. 2024;205:221-245. doi: 10.1016/bs.pmbts.2024.03.027. Epub 2024 Apr 4. Prog Mol Biol Transl Sci. 2024. PMID: 38789180 Review.
References
-
- Waring MJ, Arrowsmith J, Leach AR, et al. . An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 2015;14:475–86. - PubMed
-
- Rautio J, Kumpulainen H, Heimbach T, et al. . Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7:255–70. - PubMed
-
- Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future Med Chem 2020;12:939–47. - PubMed
-
- Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet 2021;22:658–71. - PubMed
-
- Pushpakom S, Iorio F, Eyers PA, et al. . Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019;18:41–58. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources